As #CHDI continue to bring #mHTT PET tracers to human testing, we want to share our preclinical discovery work. Here is our first F-18 based ligand, CHDI-650. https://t.co/7ryat3Ce1P
@KRHornberger I wish I tried similar advice in my graduate years why my advisor, Tom Katz, used to say: I don’t know, try spitting in your flask! I did do some enzymatic resolution those days but if I had connected the dots…
@KRHornberger He said casually minding his stuff, I don’t know, throw on some thieves! I thought, why not? The rest was history. Serendipity? Genius? It’s one of those magic moments that kept us trying in the lab
Delighted that our home-grown, RNA-targeting (small-molecule!) splice modulator for #HuntingtonsDisease has been granted Fast Track designation, accelerating development & review of this potential first-in-class, molecular glue for HD.
@HDBuzzFeed Additional info on #CHDI’s mHTT PET project can be found in Andrew Wood’s talk at the 2021 CHDI HD Therapeutic Conference https://t.co/TC5Z3yDFjv
The challenges of advancing rare neurological disease research such as #HuntingtonsDisease are discussed by Dr. Muñoz-Sanjuan and Dr. Ozdinler (expert researchers) in the webinar: https://t.co/rhrwAQRbVw #LifeSciences